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ABSTRACT
Transcriptome microarrays have become one of the
toolsofchoiceforinvestigatingthegenesinvolvedin
tumorigenesisandtumorprogression,aswellasfind-
ing new biomarkers and gene expression signatures
for the diagnosis and prognosis of cancer. Here, we
describe a new database for Integrated Tumor
Transcriptome Array and Clinical data Analysis
(ITTACA). ITTACA centralizes public datasets con-
taining both gene expression and clinical data.
ITTACA currently focuses on the types of cancer
that are of particular interest to research teams at
Institut Curie: breast carcinoma, bladder carcinoma
and uveal melanoma. A web interface allows users to
carryoutdifferentclasscomparisonanalyses,includ-
ing the comparison of expression distribution pro-
files, tests for differential expression and patient
survival analyses. ITTACA is complementary to
other databases, such as GEO and SMD, because it
offersabetterintegrationofclinicaldataanddifferent
functionalities. It also offers more options for class
comparison analyses when compared with similar
projects such as Oncomine. For example, users can
define their own patient groups according to clinical
data or gene expression levels. This added flexibility
and the user-friendly web interface makes ITTACA
especially useful for comparing personal results
with the results in the existing literature. ITTACA is
accessible online at http://bioinfo.curie.fr/ittaca.
INTRODUCTION
Recently, transcriptomic data from DNA microarrays have
allowed researchers to analyze gene expression and explore
the molecular basis of disease. Analysis of the transcriptome
allows researchers in oncology to study the regulatory mech-
anisms and biochemical pathways involved in cell transforma-
tion and tumor progression. The different types of cancer can
also be classiﬁed according to their gene expression signa-
tures. This can uncover gene expression patterns that correlate
with various anatomo-pathological or clinical characteristics
of tumors, and allow novel diagnostic biomarkers or thera-
peutic targets to be identiﬁed.
Increasing amounts of DNA microarray data are being gen-
erated as more cancer research laboratories start to use this
technology. These data are being made available to the
research community by the efforts of the Microarray Gene
Expression Data society (MGED). The MGED encourages
researchers to deposit their data in public repositories follow-
ing the Minimum Information Abouta Microarray Experiment
(MIAME) guidelines (1,2). Complete microarray datasets are
starting to become available, either as Supplementary Data in
publications or in public databases, such as Gene Expression
Omnibus (GEO) (3) or ArrayExpress (4). However, the data
are often not used to their full potential, as they are generally
analyzed with one particular clinical or biological question in
mind. It is also difﬁcult to take advantage of these public
datasets for new studies because the data are not always easy
to access and analyze. In particular, clinical data are often
missing in public databases, although it may be described
in the publication or supplied as Supplementary Data.
Integrated Tumor Transcriptome Array and Clinical data
Analysis (ITTACA) was developed by the Bioinformatics
group and the Molecular Oncology group of the Institute
Curie, a leading center in cancer research and treatment. It
aims to centralize public clinical and transcriptomic datasets
and make them available for analysis on the web. It allows
users access to transcriptome and clinical data for tumors from
experiments in published articles. ITTACA allows various
class comparison analyses to be carried out between two dif-
ferent user-deﬁned groups and to visualize gene expression
proﬁles. ITTACA allows users to reanalyze transcriptomic
data from the scientiﬁc literature in addition to presenting
the results of predeﬁned analyses. Researchers can therefore
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they can assess the differential expression of the gene they are
particularly interested in or compare their own transcriptome
array results with results in the existing literature.
DATA CONTENT
ITTACA currently contains publicly available gene expres-
sion datasets with both transcriptomic and clinical data for
human cancer tissue samples. Complete datasets were
obtained through online resources or provided on request
by the authors of publications. Currently, ITTACA focuses
on three types of cancer, for which the data integration has
been as exhaustive as possible: breast carcinoma, bladder car-
cinoma and uveal melanoma. Table 1 lists all of the public
datasets currently available in ITTACA (12 article references:
2 forbladdercarcinoma, 8for breast carcinoma and 2for uveal
melanoma).
Datasets are selected based on the availability of relevant
anatomo-clinical data. For each studied sample, the following
data must also be available: normalized gene expression data
(from different commercial or non-commercial platforms),
proper annotations for probes or probe sets (at least one iden-
tiﬁer or accession number to a public databank) and anatomo-
pathological and/or clinical characteristics.
Probe annotations, such as GeneId, Gene name, Gene sym-
bol,Unigene Identiﬁerand Gene Ontology identiﬁer,may help
users perform a query in ITTACA. Therefore, publicly avail-
able annotation tools, such as MatchMiner (5), Onto-Miner
(6) from Onto-Tools for non-commercial microarrays, and
microarray-provider annotation tools, such as NetAffx (7)
for Affymetrix GeneChip arrays, are used to enhance the ori-
ginal gene annotation datasets in ITTACA.
For the clinical data, different anatomo-pathological and
clinical characteristics are allowed in ITTACA. The following
characteristics are stored: histological information about sam-
ples, such as tissue type (normal, tumoral), tumor type (prim-
ary or not), TNM classiﬁcation, staging (G), speciﬁc markers
[like Estrogen Receptor (ER) or Progesterone Receptor for
breast cancers], clinical outcome of patients, such as patient
status (alive or dead and causes of death), relapse events and
delays and, if available, therapy information. These clinical
data were generally obtained from the Supplementary Data or
the tables in the publications.
ACCESS AND DATA ANALYSIS
The following describes the steps to follow when using
ITTACA and the different analyses available (Figure 1). In
ITTACA, the user starts bychoosingthe publication ofinterest
(Figure 1, part I). Groups of patients can then be deﬁned to be
compared ora list ofgenes ofinterestcanbe selected (orboth).
Groups can be deﬁned either by choosing patients manually or
by selecting patients based on clinical parameters, survival
time or gene expression thresholds (Figure 1, part II). Once
the patient groups and/or list of genes are selected, several
analyses can be carried out (Figure 1, part III).
ITTACA can generate Kaplan-Meier survival curves for a
set of patient groups and can compare them using the log-rank
test, which assesses the signiﬁcance of the difference in sur-
vival. Genes that are differentially expressed between these
groups can also be identiﬁed using the SAM (Signiﬁcance
Analysis of Microarrays) (8) algorithm. The user supplies
an acceptable false discovery rate (FDR) and an ordered list
of the most signiﬁcantly differentially expressed genes is
returned.
Alternatively, different statistical tests can be used to assess
the differential expression of the user-selected genes (Stu-
dent’s t-test or Wilcoxon test). Expression proﬁles can also
be viewed in ITTACA using barplots and expression distri-
bution graphs.
We will illustrate a possible use of ITTACA by taking a real
example. We wanted to conﬁrm the results found in the study
by West et al. (9) using another breast cancer dataset from the
study by van’t Veer et al. (10).
West et al. (9) looked for genes differentially expressed in
49 breast tumors between two groups having different ER
status (25 ER+ versus 24 ER) using Affymetrix oligonuc-
leotide arrays containing 7129 genes. The study used standard
binary regression models combined with singular value
Table 1. Dataset content of ITTACA
Dataset references Tissue Platform No. of samples Sources
(15) (Dataset from supervised
class analysis)
Bladder carcinoma Affymetrix HugeneFL Genechip 40 Gene Expression Omnibus
(15) (Dataset from unsupervised
class analysis)
Bladder carcinoma Affymetrix HugeneFL Genechip 31 Gene Expression Omnibus
(16) Breast carcinoma Non-commercial 58 Lund University
(17) Breast carcinoma Non-commercial 17 PNAS
(18) Breast carcinoma Non-commercial 22 NHGRI
(19) Breast carcinoma Affymetrix HG-U95Av2 89 Duke Institute for Genome
Sciences and Policy
(20) Bladder carcinoma Clontech 50 Du ¨sseldorf University
(21) Uveal melanoma Affymetrix HG-U133A and HG-U133B 25 Cancer Research
(22) Breast carcinoma Non-commercial 122 PNAS
(23) Breast carcinoma Non-commercial 99 PNAS
(24) Uveal melanoma Affymetrix HG-U95Av2 20 Duisburg-Essen University
(10) Breast carcinoma Hu25K, Agilent 117 Nature
(9) Breast carcinoma Affymetrix HugeneFL Genechip 49 PNAS
ITTACA currently contains 13 public gene expression datasets with both transcriptome and clinical data for human cancer tissue samples from bladder (3 datasets)
carcinomas, breast (8 datasets) carcinomas and uveal melanoma (2 datasets).
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Bayesian analysis. This resulted in a list of 100 differentially
expressed genes.
The data from the study by van’t Veer et al. (10) contain
gene expression proﬁles of primary breast tumors from 115
sporadic young patients (under 55 years old) and 2 familial
cases. The study by van’t Veer et al. (10) aimed to identify a
gene signature that was strongly predictive of a short interval
to distant metastases in lymph node-negative patients.
The full dataset from van’t Veer et al. (10) contains the
expression of 24 481 genes in 117 samples. From these data,
we deﬁned two groups of tumors having different ER status
(75 samples ER+ versus 42 samples ER). Next, we searched
for the 100 differentially expressed genes identiﬁed by West
et al. (9); 93 of these were present in the 24 481-gene microar-
ray used in the study by van’t Veer et al. (10). Among these
93 genes, 88 were found to be signiﬁcantly differentially
expressed between ER+ and ER groups for a P-value thresh-
old of 0.05 using the Wilcoxon test, and 38 genes were also
conﬁrmed using the Student’s t-test (the other genes did not
pass the normality test) with the same P-value threshold (with-
out correcting for multiple testing). This result, available as
Supplementary Data on the ITTACA web site, shows that
ITTACA allows a rapid ‘interpublication’ analysis using dif-
ferent groups of samples than those initially chosen in the
original studies.
ITTACA is publicly accessible at http://bioinfo.curie.fr/
ittaca. Online documentation and a video tutorial are available
on the ITTACA website demonstrating its functionality and
guiding users in their analyses.
SYSTEM IMPLEMENTATION
ITTACA is a web-based tool combining a MySQL relational
database with a dynamic web interface written in PHP and
JavaScript. The website is powered by an Apache server.
The website requires a HTML 4.0-compliant browser with
JavaScript enabled. It does not require any particular visual
plug-in tool.
The data pre-processing uses scripts written in Perl using
Perl DBI and Perl xSV packages.
Statistical analyses are performed with the R statistical
package (11) (http://www.R-project.org) and Bioconductor
(12) for SAM (8).
CONCLUSION
ITTACA is a public database that gathers published clinical
and transcriptomic datasets for bladder and breast carcinomas,
and uveal melanoma. These data are made available on the
Internet for users to reanalyze and study. Several analysis tools
allow users to deﬁne new patient groups, search for differen-
tially expressed genes, assess differential gene expression,
study patient survival time and perform some statistical ana-
lyses of gene expression.
Other tools such as Oncomine (13) allow access to public
cancer transcriptome data and allow meta-analyses to be car-
ried out on several published datasets. However, the use of
Oncomine is restricted to the analysis of groups pre-deﬁned
in the publication. GEO (3), Array Express (4) and SMD
(14) provide public non-cancer-speciﬁc transcriptome data
Figure 1. The workflow/outline of ITTACA. The first step (I, upper part of the figure) in ITTACA is the choice of the publication the user wishes to study. Then
(step II, middlepart ofthe figure) the usercandefine groupsoftumors orselect genes (orboth).Thereare four methodsfor buildingtumor groups(representedby a
right-angled box): manual choice from the list of tumors, selection based on clinical parameters or on survival time (Kaplan-Meier curve), or on a gene expression
threshold.The ovals represent the different analyses that can be carriedout with ITTACA(step III, bottom part of the figure):(A) KM is the Kaplan-Meiersurvival
curve;italsoincludesalog-ranktesttoassesssignificanceofdifferentsurvival.(B)SAM(8)isastatisticalmethodforfindingsignificantlydifferentiallyexpressed
genes in a set of microarray experiments for a given FDR. (C) The differential expression tests used by ITTACA are the Wilcoxon (non-parametric) test and the
Student’s (parametric) t-test. ITTACA allows a descriptive analysis of the data, with a gene expression barplot (D) and/or the sample’s frequency according to the
expression level for a gene (E) (frequency distribution).
Nucleic Acids Research, 2006, Vol. 34, Database issue D615repositories and are starting to offer some analysis tools
online, but they often lack clinical data and are far from
exhaustive. Therefore, ITTACA is a complementary tool in
research.
The collection of additional relevant microarray datasets is
ongoing. ITTACA will be regularly updated with new datasets
for breast and bladder carcinomas and uveal melanoma. We
intend to be as exhaustive as possible for these three cancers.
The ITTACA database is ﬂexible and will accept submissions
of datasets for other cancers. New data from pediatric tumors
are currently being integrated. We are also planning to make
ITTACA compliant with the MIAME standard (1), as well as
developingdataimportandexportfunctionalityinMAGE-ML
(MicroArray Gene Expression Markup Language) to facilitate
exchanges with other repositories.
SUPPLEMENTARY DATA
Supplementary Data are available at http://bioinfo.curie.fr/
ittaca/NAR2006SupplementaryData.
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